Page 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington , D.C. 20549 FORM 10 - K ( Mark One ) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31 , 2020 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ΤΟ Commission File Number 001-39208 Beam Therapeutics Inc. ( Exact name of Registrant as specified in its Charter ) Delaware ( State or other jurisdiction of incorporation or organization ) 26 Landsdowne Street Cambridge , MA ( Address of principal executive offices ) Title of each class Common Stock , par value $ 0.01 per share Registrant's telephone number , including area code : 857-327-8775 Securities registered pursuant to Section 12 ( b ) of the Act : 0 81-5238376 ( I.R.S. Employer Identification No. ) Trading Symbol ( s ) BEAM 02139 ( Zip Code ) Name of each exchange on which registered Nasdaq Global Select Market YES NO > NO > Securities registered pursuant to Section 12 ( g ) of the Act : None Indicate by check mark if the Registrant is a well - known seasoned issuer , as defined in Rule 405 of the Securities Act . Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15 ( d ) of the Act . YES Indicate by check mark whether the Registrant : ( 1 ) has filed all reports required to be filed by Section 13 or 15 ( d ) of the Securities Exchange Act of 1934 during the preceding 12 months ( or for such shorter period that the Registrant was required to file such reports ) , and ( 2 ) has been subject to such filing requirements for the past 90 days . YES = NO □ Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S - T ( §232.405 of this chapter ) during the preceding 12 months ( or for such shorter period that the Registrant was required to submit such files ) . YES > NO Indicate by check mark whether the registrant is a large accelerated filer , an accelerated filer , a non - accelerated filer , smaller reporting company , or an emerging growth company . See the definitions of “ large accelerated filer , ” “ accelerated filer , ” “ smaller reporting company , ” and “ emerging growth company " in Rule 12b - 2 of the Exchange Act . Large accelerated filer Non - accelerated filer Accelerated filer Smaller reporting company Emerging growth company If an emerging growth company , indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 ( a ) of the Exchange Act . □ □ DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant's definitive proxy statement that will be filed for the 2021 Annual Meeting of Stockholders are incorporated by reference in Part III . X Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404 ( b ) of the Sarbanes - Oxley Act ( 15 U.S.C. 7262 ( b ) ) by the registered public accounting firm that prepared or issued its audit report . Indicate by check mark whether the Registrant is a shell company ( as defined in Rule 12b - 2 of the Exchange Act ) . YES □ NO > The registrant's common stock began trading on the Nasdaq Global Select Market ( " Nasdaq " ) on February 6 , 2020. The aggregate market value of the voting and non - voting common stock held by non - affiliates of the registrant was $ 982,172,604 based on the closing price of the registrant's common stock on Nasdaq on June 30 , 2020 , the last business day of the registrant's most recently completed second quarter . The number of shares of registrant's common stock outstanding as of March 08 , 2021 was 62,415,481 .